Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2024 07 09T094645Z 2 LYNXMPEK680B5 RTROPTP 4 HEALTH OBESITY WEGOVY MOUNJARO
2024 07 09T094645Z 2 LYNXMPEK680B5 RTROPTP 4 HEALTH OBESITY WEGOVY MOUNJARO

Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss


Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss

LONDON (Reuters) – Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly’s own treatment Mounjaro leads to faster and greater weight loss.

The analysis was published on Monday in JAMA Internal Medicine, a medical journal. It examined health records and other data to assess the pace and percentage of weight loss for overweight and obese people taking tirzepatide – the active ingredient in Lilly’s Mounjaro and Zepbound – and semaglutide – the main ingredient in Wegovy and Ozempic.

In the absence of head-to-head randomised controlled trials comparing the two drugs, researchers used the health records and pharmacy dispensing data to analyse weight loss trajectories in 9,193 patients receiving Mounjaro and the same number of closely matched patients receiving Ozempic. The average participant weighed 242 pounds (110 kg), and about half had type 2 diabetes.

After accounting for individual risk factors, patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%, compared to patients taking Ozempic, the report found.

The two drugmakers, historically the world’s biggest producers of insulin, are the first-to-market with highly effective weight-loss drugs, a booming market that could be worth $150 billion in annual sales by the early 2030s, according to some analysts. Both are racing to increase production of their drugs, which are delivered in a once-weekly self-injection pen.

The researchers noted that Ozempic and Mounjaro are both intended for use by people with type 2 diabetes, but half of the study participants were using the drugs for weight loss only, which may have impacted the results.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

The results of this analysis were initially published in November on the website medRxiv in advance of peer review.

Shares in Novo and Lilly are at record highs on profits from the weight-loss drugs. Although Novo’s Wegovy has been on the market in the United States since 2021, Lilly’s version, sold as Zepbound in the U.S., only launched there late last year.

 

(Reporting by Greta Rosen Fondahn in Gdansk and Maggie Fick in London, Editing by Louise Heavens)

 

Recent Post: